IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Trial details
- Registry ID
- NCT05155254
- Drugs studied
- IO102-IO103, Pembrolizumab
TrialRedline tracks 3 clinical trials sponsored by IO Biotech: 1 Phase 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)NCT05155254 | IO102-IO103, Pembrolizumab | Active not recruiting | 2025-05-30Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsNCT05280314 | IO102-IO103, Pembrolizumab KEYTRUDA® | Recruiting | 2025-04-30Estimated |
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCNCT05077709 | IO102-IO103 in combination with pembrolizumab | Completed | 2025-11-30Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: ORR or PFS. After: Measure: ORR.
Before: 4 Jan 2024. After: 30 Nov 2025.
Before: Active not recruiting. After: Completed.